[PDF][PDF] Long-acting cabotegravir+ rilpivirine for HIV treatment: FLAIR week 96 results
FLAIR WEEK 96 RESULTS Page 1 Conference on Retroviruses and Opportunistic Infections;
March 8–11, 2020; Boston, MA CAB + RPV LA n=283, n (%) DTG/ABC/3TC n=283, n (%) HIV-1 …
March 8–11, 2020; Boston, MA CAB + RPV LA n=283, n (%) DTG/ABC/3TC n=283, n (%) HIV-1 …
The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch
MC Goebel, E Guajardo, TP Giordano… - Current HIV/AIDS …, 2023 - Springer
Abstract Purpose of Review Despite the availability of safe and effective oral combination
antiretroviral therapy, barriers to maintaining viral suppression remain a challenge to ending …
antiretroviral therapy, barriers to maintaining viral suppression remain a challenge to ending …
Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
C Fernandez, CL van Halsema - HIV/AIDS-Research and Palliative …, 2019 - Taylor & Francis
Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …
[PDF][PDF] Patient-reported outcomes on long-acting cabotegravir+ rilpivirine as maintenance therapy: FLAIR 48-Week results
M Murray, E Bernal, V Chounta… - The 10th IAS …, 2019 - programme.ias2019.org
MOPEB258 Page 1 10th IAS Conference on HIV Science; July 21–24, 2019; Mexico City,
Mexico 71 43 38 32 31 332927 27 34 2420 0 20 40 60 80 100 4B 8 12 16 20 24 28 32 36 40 …
Mexico 71 43 38 32 31 332927 27 34 2420 0 20 40 60 80 100 4B 8 12 16 20 24 28 32 36 40 …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …
challenges associated with daily oral HIV treatment in people living with HIV, including …
Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV
Introduction The development of long-acting (LA) drugs has changed the management of
common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva …
common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label …
H Jaeger, ET Overton, G Richmond, G Rizzardini… - The Lancet …, 2021 - thelancet.com
Background Long-acting cabotegravir and rilpivirine administered monthly or every 2
months might address the challenges associated with daily oral antiretroviral therapy. The …
months might address the challenges associated with daily oral antiretroviral therapy. The …
Patient-reported tolerability and acceptability of cabotegravir+ rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized …
M Murray, F Pulido, A Mills, M Ramgopal… - HIV Research & …, 2019 - Taylor & Francis
Background: Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality
currently under development as an alternative to daily oral ART. Objective: The LATTE-2 …
currently under development as an alternative to daily oral ART. Objective: The LATTE-2 …
Cabotegravir plus rilpivirine: first approval
A Markham - Drugs, 2020 - Springer
A regimen comprising extended release injectable suspensions of cabotegravir and
rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV …
rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV …
[HTML][HTML] Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials
G Rizzardini, ET Overton, C Orkin… - JAIDS Journal of …, 2020 - journals.lww.com
Background: Long-acting (LA) injectable regimens are a potential therapeutic option in
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …